Search

Matthias R Wabl

from San Francisco, CA
Age ~78
Get Report
Also known as:
Matthias Te Wabl, Mathias R Wabl, Matthias Wabel
Phone and address:
1515 5Th Ave, San Francisco, CA 94122
(415) 759-6585
Related to:
Elizabeth A WablMaria Wabl, 66Chiara A Wabl, 29Rafael C Wabl, 35Selina A Wabl, 28
Connected to:
Ivan F Wable, 82Kenneth Wable, 67Kevin M Wable, 56Manoj Wable, 37Mark E Wabler, 67Melissa J Wabnitz, 63David M Wabol, 58Teresa K Wabs, 52Melissa N Wabschall, 47Abigail D Wacaser, 44

Matthias Wabl Phones & Addresses

  • 1515 5Th Ave, San Francisco, CA 94122 (415) 759-6585
  • El Macero, CA
  • 1515 5Th Ave, San Francisco, CA 94122 (415) 640-2164

Work

Company: Austrianni ges.m.b.h 2015 Position: Chairman and chief strategy officer

Education

Degree: Doctorates, Doctor of Philosophy School / High School: Max - Planck Institute Specialities: Biology

Industries

Biotechnology

Resumes

Resumes

Matthias Wabl Photo 1

Chairman And Chief Executive Officer

View page
Location:
San Francisco, CA
Industry:
Biotechnology
Work:
Austrianni Ges.m.b.h
Chairman and Chief Strategy Officer
Trianni
Chairman and Chief Executive Officer
Picobella 2004 - 2008
Managing Partner
Sagres Discovery 2000 - 2004
President
Nih Small Business Innovative Research Study Section 1995 - 2001
Member
Education:
Max - Planck Institute
Doctorates, Doctor of Philosophy, Biology Karl - Franzens - Universität Graz
Master of Science, Masters, Chemical Engineering

Business Records

Name / Title
Company / Classification
Phones & Addresses
Matthias Wabl
President
TRIANNI, INC
Whol Therapy Equipment
1515 5 Ave, San Francisco, CA 94122
Matthias Wabl
Wabl Scientific LLC
Biotech Research
1515 5 Ave, San Francisco, CA 94122

Publications

Us Patents

Polynucleotides Encoding Proteins Mediating Switch Recombination

View page
US Patent:
6528284, Mar 4, 2003
Filed:
Jan 14, 2000
Appl. No.:
09/462951
Inventors:
Matthias Wabl - San Francisco CA
Rolf Jessberger - Rheinfelden, DE
Assignee:
F. Hoffman La Roche, Ltd. - Basel
The Regents of the University of California - Oakland CA
International Classification:
C12N 1512
US Classification:
435 691, 435 711, 435 712, 4352523, 43525244, 4353201, 435325, 4352542, 435348, 435471, 536 235, 530350
Abstract:
The present invention provides isolated SRTA-70 proteins that mediate immunoglobulin class switch recombination in antibody-producing cells, and methods of procuding such proteins. The invention further provides isolated polynucleotides encoding SRTA-70 proteins, as well as vectors and host cells comprising the polynucleotides. The invention further provides methods of using SRTA-70 proteins to identify agents that modulate immunoglobulin class switch.

Methods For Diagnosing And Treating Kidney Cancer

View page
US Patent:
7459280, Dec 2, 2008
Filed:
Feb 27, 2006
Appl. No.:
11/363596
Inventors:
Bruce Wang - Mountain View CA, US
Matthias Wabl - San Francisco CA, US
Assignee:
Picobella, LLC - Burlingame CA
International Classification:
G01N 33/574
US Classification:
435 723, 435 71
Abstract:
Methods, reagents and kits for diagnosing and treating kidney cancer are disclosed. An immunoassay for detecting kidney cancer is based on the relative change of the CELSR1 protein in urine or blood compared with normal tissue. An immunohistochemical assay for detecting kidney cancer is based on the relative absence of labeled antibody binding to cancerous tissue, compared with normal tissue.

Methods For Diagnosing And Treating Kidney And Colorectal Cancer

View page
US Patent:
7488584, Feb 10, 2009
Filed:
Mar 24, 2006
Appl. No.:
11/388550
Inventors:
Bruce Wang - Mountain View CA, US
Matthias Wabl - San Francisco CA, US
Assignee:
Picobella - Burlingame CA
International Classification:
G01N 33/574
US Classification:
435 723, 435 71
Abstract:
Methods, reagents and kits for diagnosing and treating cancer such as kidney or colorectal cancer are disclosed. An immunoassay for detecting kidney or colorectal cancer is based on the relative change of the ADAMTSL4 protein in urine or blood compared with normal tissue. An immunohistochemical assay for detecting kidney or colorectal cancer is based on the relative absence of labeled antibody binding to cancerous tissue, compared with normal tissue.

Methods For Screening For Prostate Cancer

View page
US Patent:
7723043, May 25, 2010
Filed:
Jan 4, 2006
Appl. No.:
11/325847
Inventors:
Bruce Wang - Mountain View CA, US
Matthias Wabl - San Francisco CA, US
Assignee:
Picobella, LP - Burlingame CA
International Classification:
G01N 33/53
G01N 33/567
G01N 33/574
C07K 16/00
US Classification:
435 71, 435 721, 435 723, 5303871, 5303877
Abstract:
Methods for diagnosing and treating prostate cancer are disclosed. In practicing the method, a subject's body-fluid sample is assayed for GPC3 protein, and the GPC3 level observed is used in determining whether the subject has an elevated GPC3 level associated with prostate cancer. Patients with such elevated levels may be treated, in accordance with the invention, with a variety of GPC3-related immunotherapy agents.

Methods For Diagnosing And Treating Kidney Cancer

View page
US Patent:
8071324, Dec 6, 2011
Filed:
Dec 2, 2008
Appl. No.:
12/326632
Inventors:
Bruce Wang - Mountain View CA, US
Matthias Wabl - San Francisco CA, US
Assignee:
Picobella, LLC - Burlingame CA
International Classification:
G01N 33/574
US Classification:
435 723, 435 71
Abstract:
Methods, reagents and kits for diagnosing and treating kidney cancer are disclosed. An immunoassay for detecting kidney cancer is based on the relative change of the CELSR1 protein in urine or blood compared with normal tissue. An immunohistochemical assay for detecting kidney cancer is based on the relative absence of labeled antibody binding to cancerous tissue, compared with normal tissue.

Genetic Tagging Strategy For Inducing And Identifying Mutations In A Genomic Sequence

View page
US Patent:
20030119190, Jun 26, 2003
Filed:
Oct 3, 2002
Appl. No.:
10/265175
Inventors:
Clifford Wang - Berkeley CA, US
Matthias Wabl - San Francisco CA, US
International Classification:
C12N015/85
C12Q001/68
C12P019/34
C12N005/06
US Classification:
435/455000, 435/091200, 435/006000, 435/326000
Abstract:
The invention features methods and compositions for introducing mutations in an endogenous host cell gene. In one embodiment, the invention features identification of genes that, when mutated, result in production of a phenotype of interest, e.g., tumor formation. In general, the invention provides a random mutagenesis system wherein a non-oncogenic, replicating vector acts as a vehicle to randomly introduce a construct comprising a hypermutation-inducing element into the genome of a host cell. Introduction of the hypermutation element in the host cell genome induces mutations (e.g., point mutations, small deletions, and/or small insertions) in genes adjacent to the integrated hypermutation element.

Polynucleotides Encoding Proteins Mediating Switch Recombination

View page
US Patent:
20030143611, Jul 31, 2003
Filed:
Jan 10, 2003
Appl. No.:
10/339884
Inventors:
Matthias Wabl - San Francisco CA, US
Rolf Jessberger - Rheinfelden, DE
International Classification:
C12Q001/68
G01N033/53
C07K014/47
C12P021/02
C12N005/06
C07K016/18
US Classification:
435/006000, 435/069100, 435/007100, 435/320100, 435/325000, 530/350000, 530/388100
Abstract:
The present invention relates to the isolation, purification and characterization of proteins mediating switch recombination. It further relates to recombinant SRTA-70 proteins, DNA sequences encoding these proteins, vectors containing these DNA sequences and hosts containing these vectors. The use of these proteins for identifying agonists or antagonists and other proteins involved in class switch recombination is also provided.

Methods For Identifying Agents That Modulate Mast Cell Degranulation

View page
US Patent:
20030166018, Sep 4, 2003
Filed:
Mar 1, 2002
Appl. No.:
10/087144
Inventors:
Matthias Wabl - San Francisco CA, US
Rolf Jessberger - White Plains NY, US
International Classification:
G01N033/567
US Classification:
435/007210
Abstract:
The invention provides screening methods to identify agents that modulate a level or an activity of a SWAP-70 protein in a degranulation competent cell; agents that reduce a level or an activity of a SWAP-70 protein, including agents identified by the screening methods; and pharmaceutical compositions comprising such agents. The present invention further provides methods of reducing degranulation in a degranulation competent cell, such as a mast cell or basophil. The methods generally involve reducing a level or activity of a SWAP-70 protein in a degranulation competent cell. The invention further provides methods of treating a mast cell-mediated disorder in an individual.

Isbn (Books And Publications)

1968: Ein Heimatroman

View page
Author

Matthias Wabl

ISBN #

3222124310

Control profile
Matthias R Wabl from San Francisco, CA, age ~78 Get Report